Next Hurdles For COVID-19 Vaccine Development: Selecting Endpoints, Getting Enough Subjects
US FDA's Peter Marks and industry execs discuss challenges in moving candidate vaccines to Phase II/III trials, including international regulatory alignment on clinical endpoints and other issues. J&J's Paul Stoffels says it is going to be a 'Herculean task' to conduct placebo-controlled studies in 30,000 to 100,000 people.
You may also be interested in...
Three host-targeted immune modulators, three anticoagulants, and three to six neutralizing antibodies are to be tested in ACTIV clinical trials, FNIH's David Wholley tells DIA meeting.
Principal Deputy Commissioner Amy Abernethy suggests FDA may clear a COVID-19 vaccine on smaller than usual clinical datasets and rely on real-world data to fill in the gaps. Abernethy said a new public-private partnership is starting to explore how it can use real-world data and evidence for COVID-19 vaccine evaluation.
The world is waiting for a coronavirus vaccine – but can we depend on it, and when will it arrive? A visual tracker of key developments from leading candidates.